| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_575d6e6472b7186b5d8f2a3ec647a131
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_87d8bfe895f45f54e32155fa622fb608 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0073
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0078
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0019
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-522
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-26 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-19
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-522
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00 |
| filingDate |
2020-05-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2021-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_51b0b3ac5acd1cdfff1b14db4584b017
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_18d6f2ee9a3eca01b7bb61f2615e79db |
| publicationDate |
2021-12-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-11207326-B2 |
| titleOfInvention |
Accelerated treatment of COVID-19 and SAR's type viruses |
| abstract |
The present invention provides a solution mixture of 1.8 to 3.7% hypertonic saline, 70 to 85% ethanol as solvent alternating with 10 milliliters 50 to 90% of 75 to 110 mg theobromine in a nebulized aerosol for inhalation by COVID-19 and SARS patients. Alternatively, theobromine may be infused alternating with inhaled nebulized exogenous pulmonary surfactant as replacement. For advanced COVID-19, SARS patients, the inhalation described above may be alternated with an intravenous solution of 1.8% to 2.2% hypertonic solution of theobromine as 450 mg to 650 mg in ethanol, twice daily. |
| priorityDate |
2020-05-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |